Madrigal Pharmaceuticals

HQ
Conshohocken, Pennsylvania, USA
430 Total Employees
Year Founded: 2016

Similar Companies Hiring

Software • Manufacturing • Machine Learning • Information Technology • Generative AI • Conversational AI
8 Offices
1200 Employees
Telehealth • Social Impact • Pharmaceutical • Healthtech
New York City, NY
13 Employees
Pharmaceutical • Logistics • Healthtech
12 Offices
46000 Employees
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist that is designed to target key underlying causes of NASH in the liver. Resmetirom is currently being evaluated in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in patients with NASH. For more information, visit www.madrigalpharma.com

Madrigal Pharmaceuticals Offices

OnSite Workspace

Employees work from physical offices.

Typical time on-site: None
HQConshohocken, Pennsylvania, USA